A Study of Real-world Treatment of Adults With Urothelial Cancer in South Korea and Saudi Arabia
NCT06505746 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 287
Last updated 2025-03-24
Summary
Cancer in the bladder lining (urothelial cancer) can be treated in many ways. One way is to directly attack cancer cells. Enfortumab vedotin is a treatment that can do this. Another way is to help the body's immune system find and attack cancer cells. Avelumab is a treatment that can do this. Both treatments were recently approved in some countries.
Doctors have standard clinical practice guidelines to help them treat people with cancer. This study is about collecting information on how adults with urothelial cancer are treated in standard clinical practice. The people in this study will have locally advanced or metastatic urothelial cancer. Locally advanced means the cancer has spread to tissue close by.
Metastatic means the cancer has spread to other parts of the body.
The goal of this study is to learn how people with urothelial cancer receive medical care in clinics in South Korea and Saudi Arabia. The main goals are to learn more about the people receiving treatments, and the treatments they receive.
This study is about collecting information only. The individual's doctor decides on treatment, not the study sponsor (Astellas).
Information will be collected from the people's medical records. This will include 12 months before treatment starts, and during treatment. Also, doctors will answer questions in interviews and surveys about how they care for people with urothelial cancer.
Conditions
- Metastatic Urothelial Cancer
Interventions
- OTHER
-
No intervention
No investigational drug will be administered to participants in this study.
Sponsors & Collaborators
-
Astellas Pharma Singapore Pte. Ltd.
lead INDUSTRY
Principal Investigators
-
Medical Director · Astellas Pharma Singapore Pte. Ltd.
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-08-29
- Primary Completion
- 2025-01-31
- Completion
- 2025-01-31
Countries
- South Korea
Study Locations
More Related Trials
-
Cisplatin-Based Chemotherapy Followed by Maintenance Avelumab in UTUC
NCT07225374 ·Status: RECRUITING ·Phase: PHASE2
-
A Study to Survey Adults in South Korea With Cancer Who Receive PADCEV Injection
NCT06011954 ·Status: RECRUITING
-
Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study
NCT05092958 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium
NCT00407485 ·Status: COMPLETED ·Phase: PHASE2
-
A Safety Study of Enfortumab Vedotin in Indian Adults With Urothelial Cancer
NCT06862219 ·Status: RECRUITING ·Phase: PHASE4
-
Tetra-modality Bladder Preservation Strategies in Muscle-invasive Bladder Cancer: TURBT+ Chemo/Immunotherapy+ Radiation Therapy+ Maintenance Immunotherapy vs. W&W
NCT06686381 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer
NCT03244384 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Surgery With or Without Chemotherapy in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer
NCT00003725 ·Status: UNKNOWN ·Phase: PHASE3
-
Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer
NCT01050504 ·Status: RECRUITING
-
KHK2455 (IDO Inhibitor) Plus Avelumab in Adult Subjects With Advanced Bladder Cancer
NCT03915405 ·Status: TERMINATED ·Phase: PHASE1
-
Study of Weekly Radiotherapy for Bladder Cancer
NCT01810757 ·Status: COMPLETED ·Phase: NA
-
Nivolumab and RT in Treating Patients With Localized/Locally Advanced Urothelial Bladder Cancer Ineligible for Chemo
NCT03421652 ·Status: COMPLETED ·Phase: PHASE2
-
Criteria for Selecting First-line Metastatic Treatment for Patients With Urothelial Carcinoma
NCT07339878 ·Status: RECRUITING
-
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
NCT05987241 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Atezolizumab Immunotherapy, in Immunotherapy Naive Patients With Urinary Tract Squamous Cell Carcinoma (UTSCC).
NCT05038657 ·Status: UNKNOWN ·Phase: PHASE2
-
Cryoablation With Pembrolizumab Or Avelumab In Urothelial Carcinoma
NCT04701918 ·Status: COMPLETED ·Phase: PHASE2
-
Adjuvant Radioimmunotherapy Compared With Adjuvant Chemotherapy for UTUC
NCT06120374 ·Status: RECRUITING
-
Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer
NCT04579224 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Radiation Therapy and Pembrolizumab in Treating Patients With Localized Urothelial Bladder Cancer
NCT03419130 ·Status: WITHDRAWN ·Phase: PHASE2
-
Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in Urothelial Carcinoma
NCT05154994 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer
NCT04878029 ·Status: RECRUITING ·Phase: PHASE1
-
First-line Gemcitabine/Cisplatin +/- Avelumab in Locally Advanced or Metastatic Bladder Carcinoma
NCT03324282 ·Status: TERMINATED ·Phase: PHASE2
-
A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 1)
NCT02951767 ·Status: COMPLETED ·Phase: PHASE2
-
TRC105 in Adults With Advanced/Metastatic Urothelial Carcinoma
NCT01328574 ·Status: COMPLETED ·Phase: PHASE2
-
Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer
NCT03601455 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2